Illumina Inc. (ILMN) exhibits 66.1% gross margins and 18.2% return on invested capital within Health Care (Medical Specialities), balanced against a 47.5x enterprise multiple and 4.8% implied options volatility.
Sustained 66.1% gross profitability converts into 18.6% operating margin and 18.2% ROIC, outpacing sector cost of capital.
ROIC: 18.2% // GM: 66.1%YoY revenue trajectory of -0.7% paired with 2.13% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -0.7% // FCF YLD: 2.13%Altman Z-Score of 9.52 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 9.52 // F-SCORE: 8/9Trading at 51.5x trailing P/E (47.9x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 51.5x // EV/EBITDA: 47.5xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $235.99 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Medical Specialities require continuous execution to defend 19.6% net margins.
NET MARGIN: 19.6% // D/E: 0.49x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for ILMN & activate live FRED threshold breach alerts.